Company Overview of iCeutica Inc.
iCeutica Inc. develops a pipeline of reformulated and improved products. It offers SoluMatrix platform, a drug reformulation and delivery technology for poorly water-soluble compounds. The company was founded in 2003 and is based in Philadelphia, Pennsylvania with a facility in Perth, Australia. As of April 28, 2011, iCeutica Inc. operates as a subsidiary of Iroko Pharmaceuticals, LLC.
1 Crescent Drive
Navy Yard Corporate Center
Philadelphia, PA 19112
Founded in 2003
Key Executives for iCeutica Inc.
Vice President of Clinical Development and Regulatory Affairs
Vice President of Research and Development
Compensation as of Fiscal Year 2014.
iCeutica Inc. Key Developments
iCeutica Inc. Names Jyrki Mattila as Chief Business Officer
Dec 16 13
iCeutica Inc. hired Jyrki Mattila as chief business officer. Mattila served as president and CEO of LZ Therapeutics Inc.
iCeutica Inc. Appoints Jyrki Mattila as Chief Business Officer
Oct 16 13
iCeutica Inc. announced that Jyrki Mattila, M.D., Ph.D., has joined the company as Chief Business Officer. Dr. Mattila brings over twenty-five years of business development and management experience to iCeutica and has negotiated and closed over fifty business agreements, including in- and out- licensing, co-marketing, collaboration and product acquisition arrangements. Prior to joining iCeutica, Dr. Mattila served as President and CEO of LZ Therapeutics Inc.
iCeutica Announces Positive Top-Line Phase 1 Results of ICE 1201
Sep 12 13
iCeutica announced positive top-line results from its Phase 1 trial of ICE 1201, a submicron version of metaxalone, a muscle relaxant indicated for the treatment of acute, painful musculoskeletal conditions. Trial results demonstrated improved oral bioavailability, decreased pharmacokinetic variability, more rapid absorption and decreased food effect, when compared to the currently marketed metaxalone product, SKELAXIN. Both ICE 1201 and SKELAXIN were well tolerated, with only mild adverse. The Phase 1 trial enrolled 20 healthy volunteers. Utilizing a four-way crossover design, the study evaluated patients’ response to a 300mg dose of ICE 1201, a 600mg dose of ICE 1201, an 800mg dose of SKELAXIN®, and a 600mg dose of ICE 1201 following a fatty meal.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|